Teams link: Join the Meeting Now

Meeting ID: 234 297 242 669 890

Passcode: EG2uo7X8

Learning Objectives: 

  • Describe cefiderocol’s MOA, PK/PD, spectrum, and susceptibility in multidrug-resistant Gram-negative infections.​

  • Evaluate the CREDIBLE-CR, GAME CHANGER, and APEK trials, with particular attention to efficacy and mortality. ​

  • Apply 2026 IDSA guidance to evaluate cefiderocol place in treatment for resistant Gram-negative infections, including CRE, CRAB, and Stenotrophomonas maltophilia.​

Session date: 
10/29/2026 - 2:00pm to 3:00pm CDT
Location: 
In-person and Virtually
Will be determined by room availability
600 Highland Ave
Madison, WI 53705
United States
See map: Google Maps
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
Add to calendar: 
Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
Sarah Aragon
Aaron Dwyer
Payton Reiner
Emily Willihnganz